We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




RFA Safe for Treating Liver Tumors

By HospiMedica staff writers
Posted on 22 Nov 2004
A study has found radiofrequency ablation (RFA) a safe and effective treatment for eradicating liver tumors in contact with the gastrointestinal (GI) tract.

The study analyzed 41 patients with a liver tumor abutting the GI tract. More...
After RFA ablation was performed on these patients, 34 of the 41 tumors were found to be eradicated, with no bowel-related complications. Previously, investigators have warned that RFA might cause injuries when tumors are touching the GI tract. The study was conducted by researchers at the Samsung Medical Center (Seoul, South Korea).

In a second study, conducted at Brigham and Women's Hospital (Boston, MA, USA), researchers found that injecting alcohol into a liver tumor immediately prior to RFA makes the procedure more effective, in that more of the tumor is destroyed, so patients can undergo fewer RFA treatments. They found that the combination is also effective in other parts of the body.

"We have used the combination therapy successfully in other parts of the body, such as with bone and soft-tissue tumors. However, the combination must be used carefully in areas where alcohol leakage could be deleterious, such as in the lung where normal tissue may be affected,” said lead author Sridhar Shankar, M.D., of the University of Massachusetts, Worcester (USA). Both studies were published in the November 2004 issue of the American Journal of Roentgenology.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gas Consumption Analyzer
Anesthetic Gas Consumption Analyzer
Silver Member
X-Ray QA Device
Accu-Gold+ Touch Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.